Co-encapsulation of an antigen and CpG oligonucleotides into PLGA microparticles by TROMS technology

European Journal of Pharmaceutics and Biopharmaceutics

Volumn 70, Issue 1, 2008, Pages 98-108

  Román, Beatriz San ^a   Irache, Juan M ^a   Gómez, Sara ^a   Tsapis, Nicolas ^b,c   Gamazo, Carlos ^a   Espuelas, María Socorro ^a  

^a UNIVERSITY OF NAVARRA   (Spain)

^b UNIVERSITÉ PARIS SACLAY   (France)

^c CNRS   (France)

Author keywords

Antigen; CpG sequences; Microparticles; Poly(lactic co glycolic) acid; Th1 Th2 immune response

Indexed keywords

ANTIGEN; CHITOSAN; CPG OLIGODEOXYNUCLEOTIDE; GAMMA INTERFERON; IMMUNOGLOBULIN CLASS; IMMUNOGLOBULIN G1; IMMUNOGLOBULIN G2A; OVALBUMIN; POLYGLACTIN; POLYMER; RESOMER RG 502; RESOMER RG 756; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANTIBODY RESPONSE; ARTICLE; CELLULAR IMMUNITY; COMPLEX FORMATION; CONTROLLED STUDY; DRUG FORMULATION; ENCAPSULATION; FEMALE; HUMORAL IMMUNITY; IMMUNIZATION; MOUSE; NONHUMAN; TECHNOLOGY; TH1 CELL; TOTAL RECIRCULATION ONE MACHINE SYSTEM;

ADJUVANTS, IMMUNOLOGIC; ANIMALS; ANTIBODIES; ANTIBODY FORMATION; ANTIGENS; CELLS, CULTURED; CHEMISTRY, PHARMACEUTICAL; CHITOSAN; DENDRITIC CELLS; DRUG CARRIERS; FEMALE; IMMUNITY, CELLULAR; INJECTIONS, INTRADERMAL; INTERFERON-GAMMA; INTERLEUKIN-4; LACTIC ACID; MICE; MICE, INBRED BALB C; MICE, INBRED C57BL; OLIGODEOXYRIBONUCLEOTIDES; OVALBUMIN; PARTICLE SIZE; POLYGLYCOLIC ACID; SOLUBILITY; TECHNOLOGY, PHARMACEUTICAL; TH1 CELLS; TIME FACTORS; VACCINES;

EID: 50149114680     PISSN: 09396411     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejpb.2008.03.015     Document Type: Article

References (38)

1. Thomas D.P., Viudes A., Monteagudo C., Lazzell A.L., Saville S.P., and Lopez-Ribot J.L. A proteomic-based approach for the identification of Candida albicans protein components present in a subunit vaccine that protects against disseminated candidiasis. Proteomics 6 (2006) 6033-6041
2. Ochoa-Reparaz J., Garcia B., Solano C., Lasa I., Irache J.M., and Gamazo C. Protective ability of subcellular extracts from Salmonella Enteritidis and from a rough isogenic mutant against salmonellosis in mice. Vaccine 23 (2005) 1491-1501
3. Gupta R.K., and Siber G.R. Adjuvants for human vaccines - current status, problems and future prospects. Vaccine 13 (1995) 1263-1276
4. Robinson D.S., Hamid Q., Ying S., Tsicopoulos A., Barkans J., Bentley A.M., Corrigan C., Durham S.R., and Kay A.B. Predominant TH2-like bronchoalveolar T-lymphocyte population in atopic asthma. N. Engl. J. Med. 326 (1992) 298-304
5. Clemmensen O., and Knudsen H.E. Contact sensitivity to aluminium in a patient hyposensitized with aluminium precipitated grass pollen. Contact Dermatitis 6 (1980) 305-308
6. Estevan M., Irache J.M., Grillo M.J., Blasco J.M., and Gamazo C. Encapsulation of antigenic extracts of Salmonella enterica serovar Abortusovis into polymeric systems and efficacy as vaccines in mice. Vet. Microbiol. 118 (2006) 124-132
7. Chattaraj S.C., Rathinavelu A., and Das S.K. Biodegradable microparticles of influenza viral vaccine: comparison of the effects of routes of administration on the in vivo immune response in mice. J. Control. Release 58 (1999) 223-232
8. Reddy C.G., Chalasani V., and Pathma-Nathan N. Splenic preservation: an additional haemostatic measure during mesh splenorrhaphy. ANZ J. Surg. 74 (2004) 596-597
9. Sinha V.R., and Trehan A. Biodegradable microspheres for protein delivery. J. Control. Release 90 (2003) 261-280
10. O'Hagan D.T., Jeffery H., Roberts M.J., McGee J.P., and Davis S.S. Controlled release microparticles for vaccine development. Vaccine 9 (1991) 768-771
11. Halpern M.D., Kurlander R.J., and Pisetsky D.S. Bacterial DNA induces murine interferon-gamma production by stimulation of interleukin-12 and tumor necrosis factor-alpha. Cell Immunol. 167 (1996) 72-78
12. Klinman D.M., Yi A.K., Beaucage S.L., Conover J., and Krieg A.M. CpG motifs present in bacteria DNA rapidly induce lymphocytes to secrete interleukin 6, interleukin 12, and interferon gamma. Proc. Natl. Acad. Sci. USA 93 (1996) 2879-2883
13. Wu K.Y., Wu M., Fu M.L., Li H., Yang Y., Zhang H., Cheng C., Wang Z.Z., Wang X.Y., Lu X.B., Liu D.G., Li H., and Gao R. A novel chitosan CpG nanoparticle regulates cellular and humoral immunity of mice. Biomed. Environ. Sci. 19 (2006) 87-95
14. Jahrsdorfer B., and Weiner G.J. CpG oligodeoxynucleotides for immune stimulation in cancer immunotherapy. Curr. Opin. Investig. Drugs 4 (2003) 686-690
15. Horner A.A., Takabayashi K., Beck L., Sharma B., Zubeldia J., Baird S., Tuck S., Libet L., Spiegelberg H.L., Liu F.T., and Raz E. Optimized conjugation ratios lead to allergen immunostimulatory oligodeoxynucleotide conjugates with retained immunogenicity and minimal anaphylactogenicity. J. Allergy Clin. Immunol. 110 (2002) 413-420
16. Horner A.A., and Raz E. Immunostimulatory sequence oligodeoxynucleotide-based vaccination and immunomodulation: two unique but complementary strategies for the treatment of allergic diseases. J. Allergy Clin. Immunol. 110 (2002) 706-712
17. Diwan M., Tafaghodi M., and Samuel J. Enhancement of immune responses by co-delivery of a CpG oligodeoxynucleotide and tetanus toxoid in biodegradable nanospheres. J. Control. Release 85 (2002) 247-262
18. Steinberg A.D., Krieg A.M., Gourley M.F., and Klinman D.M. Theoretical and experimental approaches to generalized autoimmunity. Immunol. Rev. 118 (1990) 129-163
19. Gomes dos Santos A.L., Bochot A., Doyle A., Tsapis N., Siepmann J., Siepmann F., Schmaler J., Besnard M., Behar-Cohen F., and Fattal E. Sustained release of nanosized complexes of polyethylenimine and anti-TGF-beta 2 oligonucleotide improves the outcome of glaucoma surgery. J. Control. Release 112 (2006) 369-381
20. del Barrio G.G., Novo F.J., and Irache J.M. Loading of plasmid DNA into PLGA microparticles using TROMS (Total Recirculation One-Machine System): evaluation of its integrity and controlled release properties. J. Control. Release 86 (2003) 123-130
21. Estevan M., Gamazo C., Grillo M.J., Del Barrio G.G., Blasco J.M., and Irache J.M. Experiments on a sub-unit vaccine encapsulated in microparticles and its efficacy against Brucella melitensis in mice. Vaccine 24 (2006) 4179-4187
22. Laemmli U.K. Cleavage of structural proteins during the assembly of the head of bacteriophage T4. Nature 227 (1970) 680-685
23. Fairbanks G., Steck T.L., and Wallach D.F. Electrophoretic analysis of the major polypeptides of the human erythrocyte membrane. Biochemistry 10 (1971) 2606-2617
24. Gamazo C., Winter A.J., Moriyon I., Riezu-Boj J.I., Blasco J.M., and Diaz R. Comparative analyses of proteins extracted by hot saline or released spontaneously into outer membrane blebs from field strains of Brucella ovis and Brucella melitensis. Infect. Immun. 57 (1989) 1419-1426
25. Arnedo A., Espuelas S., and Irache J.M. Albumin nanoparticles as carriers for a phosphodiester oligonucleotide. Int. J. Pharm. 244 (2002) 59-72
26. Sarobe P., Lasarte J.J., Zabaleta A., Arribillaga L., Arina A., Melero I., Borras-Cuesta F., and Prieto J. Hepatitis C virus structural proteins impair dendritic cell maturation and inhibit in vivo induction of cellular immune responses. J. Virol. 77 (2003) 10862-10871
27. Faquim-Mauro E.L., and Macedo M.S. Induction of IL-4-dependent, anaphylactic-type and IL-4-independent, non-anaphylactic-type IgG1 antibodies is modulated by adjuvants. Int. Immunol. 12 (2000) 1733-1740
28. Garcia del Barrio G., Hendry J., Renedo M.J., Irache J.M., and Novo F.J. In vivo sustained release of adenoviral vectors from poly(d,l-lactic-co-glycolic) acid microparticles prepared by TROMS. J. Control. Release 94 (2004) 229-235
29. Joseph A., Louria-Hayon I., Plis-Finarov A., Zeira E., Zakay-Rones Z., Raz E., Hayashi T., Takabayashi K., Barenholz Y., and Kedar E. Liposomal immunostimulatory DNA sequence (ISS-ODN): an efficient parenteral and mucosal adjuvant for influenza and hepatitis B vaccines. Vaccine 20 (2002) 3342-3354
30. Yamada Y., Kogure K., Nakamura Y., Inoue K., Akita H., Nagatsugi F., Sasaki S., Suhara T., and Harashima H. Development of efficient packaging method of oligodeoxynucleotides by a condensed nano particle in lipid envelope structure. Biol. Pharm. Bull. 28 (2005) 1939-1942
31. Singh M., Ott G., Kazzaz J., Ugozzoli M., Briones M., Donnelly J., and O'Hagan D.T. Cationic microparticles are an effective delivery system for immune stimulatory cpG DNA. Pharm. Res. 18 (2001) 1476-1479
32. Tafaghodi M., Sajadi Tabassi S.A., and Jaafari M.R. Induction of systemic and mucosal immune responses by intranasal administration of alginate microspheres encapsulated with tetanus toxoid and CpG-ODN. Int. J. Pharm. 319 (2006) 37-43
33. Murillo M., Gamazo C., Irache J.M., and Goni M.M. Polyester microparticles as a vaccine delivery system for brucellosis: influence of the polymer on release, phagocytosis and toxicity. J. Drug Target 10 (2002) 211-219
34. Tabata Y., and Ikada Y. Macrophage activation through phagocytosis of muramyl dipeptide encapsulated in gelatin microspheres. J. Pharm. Pharmacol. 39 (1987) 698-704
35. Tengvall S., Lundqvist A., Eisenberg R.J., Cohen G.H., and Harandi A.M. Mucosal administration of CpG oligodeoxynucleotide elicits strong CC and CXC chemokine responses in the vagina and serves as a potent Th1-tilting adjuvant for recombinant gD2 protein vaccination against genital herpes. J. Virol. 80 (2006) 5283-5291
36. Westwood A., Elvin S.J., Healey G.D., Williamson E.D., and Eyles J.E. Immunological responses after immunisation of mice with microparticles containing antigen and single stranded RNA (polyuridylic acid). Vaccine 24 (2006) 1736-1743
37. Martinez Gomez J.M., Fischer S., Csaba N., Kundig T.M., Merkle H.P., Gander B., and Johansen P. A protective allergy vaccine based on CpG- and protamine-containing PLGA microparticles. Pharm. Res. 24 (2007) 1927-1935
38. Zhang X.Q., Dahle C.E., Weiner G.J., and Salem A.K. A comparative study of the antigen-specific immune response induced by co-delivery of CpG ODN and antigen using fusion molecules or biodegradable microparticles. J. Pharm. Sci. 96 (2007) 3283-3292